0.1% 溴芬酸钠与0.1% 吡嘧司特钾治疗过敏性结膜炎的比较。
Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
作者信息
Miyake-Kashima Minori, Takano Yoji, Tanaka Mari, Satake Yoshiyuki, Kawakita Tetsuya, Dogru Murat, Asano-Kato Naoko, Fukagawa Kazumi, Fujishima Hiroshi
机构信息
Department of Ophthalmology, Tokyo Dental College, Chiba, Ichikawa, Japan.
出版信息
Jpn J Ophthalmol. 2004 Nov-Dec;48(6):587-90. doi: 10.1007/s10384-004-0127-2.
PURPOSE
We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients.
METHODS
Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment.
RESULTS
Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs.
CONCLUSION
Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.
目的
我们比较了一种新型非甾体抗炎药滴眼液0.1%溴芬酸钠（Bromfenac）与一种抗过敏药0.1%吡嘧司特钾（Pemirolast）对日本季节性过敏性结膜炎患者的治疗效果。
方法
22名季节性过敏性结膜炎患者参与了本研究。一只眼睛用Bromfenac滴眼液治疗，对侧眼睛用Pemirolast滴眼液治疗，为期1周。在治疗前后对通过裂隙灯检查评估的主观眼部症状和客观眼部体征进行评分并记录。
结果
两种药物在1周后均显著减轻了眼部体征，但未减轻症状。两种药物在主观症状或客观体征方面未观察到显著差异。10名患者（45.5%）选择Bromfenac更有效，9名患者（40.9%）选择Pemirolast，3名患者认为两种药物疗效无差异。
结论
溴芬酸钠在治疗过敏性结膜炎方面与吡嘧司特钾一样安全有效。
Zotero 插件